Literature DB >> 17310341

Costs and quality of life of multiple sclerosis in the United Kingdom.

Gisela Kobelt1, Jenny Berg, P Lindgren, J Kerrigan, N Russell, R Nixon.   

Abstract

This cost-of-illness analysis for the United Kingdom is part of a Europe-wide study on the costs of multiple sclerosis (MS). The objective was to analyze the costs and quality of life (utility) related to the level of disease severity. People with MS from a database administered by a UK charity (the MS Trust) were asked to participate in the survey by answering a postal questionnaire. In addition to details on the disease (type of disease, relapses, level of functional disability), the questionnaire asked for information on all resource consumption, medical, non-medical, work absence and informal care as well as utility. The response rate was 19%, and a total of 2048 people were included. The mean age of the cohort was 51 years, and 23% of people were > or =60 years of age. Disease severity was concentrated in people with moderately severe MS (Expanded Disability Status Scale [EDSS] score of 4 to 6.5), with 21, 60 and 19% of people reporting mild, moderate and severe disease, respectively. Costs and utility are highly correlated with disease severity. Mean annual costs for all people in the study increase from approximately pound 12.000 at an EDSS score <4 to almost pound 60.000 at an EDSS score > or =7. In particular, employment rates are reduced from 82% in early disease to 2% at an EDSS score of 8, while the costs of inpatient care, investments, informal care and productivity losses increase by more than tenfold between an EDSS score of 0-1 and a score > or =7. Utility decreases from 0.92 at an EDSS score of 0 to a state worse than death in the most severe state (-0.18 at an EDSS score of 9). Compared to the results in an earlier cost study in the United Kingdom using a comparable methodology, costs have substantially increased, by roughly 40%. Part of the increase is due to a higher use of disease-modifying drugs and, possibly linked with this, a higher use of ambulatory care and services. Another part of the increase is most likely due to an increased age in the current sample, with more patients on early retirement due to MS and more intense use of informal care. However, another reason may lie in the methodology, e.g. different unit costs or differences in the sample distribution, despite a similar mean EDSS score of 5.1.

Entities:  

Mesh:

Year:  2006        PMID: 17310341     DOI: 10.1007/s10198-006-0380-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  27 in total

Review 1.  The radiologically isolated syndrome: take action when the unexpected is uncovered?

Authors:  Johann Sellner; Lucas Schirmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2010-05-26       Impact factor: 4.849

2.  Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.

Authors:  Trudy Owens; Nikos Evangelou; David K Whynes
Journal:  Eur J Health Econ       Date:  2012-01-24

3.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Burden of a multiple sclerosis relapse: the patient's perspective.

Authors:  Merrikay Oleen-Burkey; Jane Castelli-Haley; Maureen J Lage; Kenneth P Johnson
Journal:  Patient       Date:  2012       Impact factor: 3.883

5.  Multiple sclerosis: relapses, resource use, and costs.

Authors:  A J Hawton; C Green
Journal:  Eur J Health Econ       Date:  2015-10-05

6.  Falls in People with Multiple Sclerosis: Risk Identification, Intervention, and Future Directions.

Authors:  Susan Coote; Laura Comber; Gillian Quinn; Carme Santoyo-Medina; Alon Kalron; Hilary Gunn
Journal:  Int J MS Care       Date:  2020-09-14

Review 7.  Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Authors:  Jessica Sharac; Paul McCrone; Ramon Sabes-Figuera
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 8.  Economic burden of multiple sclerosis: a systematic review of the literature.

Authors:  Huseyin Naci; Rachael Fleurence; Julie Birt; Amy Duhig
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

9.  Chronical illness and maternity: life conditions, quality of life and coping in women with multiple sclerosis.

Authors:  Sabine Twork; Markus Wirtz; Sabine Schipper; Jörg Klewer; Antje Bergmann; Joachim Kugler
Journal:  Qual Life Res       Date:  2007-10-05       Impact factor: 4.147

10.  Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

Authors:  John P Zajicek; Wendy M Ingram; Jane Vickery; Siobhan Creanor; Dave E Wright; Jeremy C Hobart
Journal:  BMC Neurol       Date:  2010-10-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.